17:29 , Sep 28, 2018 |  BC Week In Review  |  Clinical News

Innovent's PD-1 Inhibitor leads to 22.7% ORR in Phase Ib for NETs

Innovent Biologics Inc. (Suzhou, China) said anti-PD-1 antibody sintilimab (IBI308) led to an objective response rate (ORR) of 22.7% in 22 evaluable patients with neuroendocrine tumors (NETs) who failed standard therapy in a Chinese Phase...
21:57 , Sep 21, 2018 |  BC Extra  |  Clinical News

Innovent reports Chinese NET, NSCLC data for PD-1 mAb

Innovent Biologics Inc. (Suzhou, China) presented data this week from neuroendocrine tumor and non-small cell lung cancer cohorts in its Chinese Phase Ib trial of anti-PD-1 mAb sintilimab (IBI308). Data were presented at the Chinese...
18:31 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

Chinese regulators reviewing pair of BeiGene therapies

BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) said Aug. 31 that China's National Medical Products Administration accepted an NDA for anti-PD-1 mAb tislelizumab (BGB-A317) to treat relapsed or refractory classical Hodgkin lymphoma (cHL). The news follows BeiGene's Aug....
19:19 , Aug 31, 2018 |  BC Extra  |  Company News

Chinese regulators reviewing pair of BeiGene therapies

BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) said Friday that China's National Medical Products Administration accepted an NDA for anti-PD-1 mAb tislelizumab (BGB-A317) to treat relapsed or refractory classical Hodgkin lymphoma (cHL). The news follows BeiGene's Aug. 26...
16:40 , Aug 3, 2018 |  BC Week In Review  |  Financial News

BeiGene prices Hong Kong listing

BeiGene Ltd. (NASDAQ:BGNE) raised on Aug. 2 HK$7.1 billion (US$902.7 million) through the sale of 65.6 million shares at HK$108 in its listing on the Hong Kong stock exchange. BeiGene, which priced the offering toward...
18:30 , Jul 27, 2018 |  BC Extra  |  Financial News

BeiGene's proposed HKEX listing could rake in over $900M

BeiGene Ltd. (NASDAQ:BGNE) proposed to raise up to HK$7.3 billion ($932.7 million) in a follow-on on the Hong Kong stock exchange through the sale of 65.6 million shares at HK$94.40-HK$111.60. At the HK$103 midpoint, BeiGene...
15:38 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

New data, designation bolster BeiGene's planned submissions

BeiGene Ltd. (NASDAQ:BGNE) reported response rate data from a pivotal, Chinese Phase II trial of PD-1 inhibitor tislelizumab (BGB-A317) to treat classical Hodgkin's lymphoma (cHL), for which the company is planning a regulatory submission this...
18:23 , Jul 23, 2018 |  BC Extra  |  Clinical News

New data, designation bolster BeiGene's planned submissions

BeiGene Ltd. (NASDAQ:BGNE) reported response rate data Sunday from a pivotal, Chinese Phase II trial of PD-1 inhibitor tislelizumab (BGB-A317) to treat classical Hodgkin's lymphoma (cHL), for which the company is planning a regulatory submission...
02:59 , May 5, 2018 |  BioCentury  |  Strategy

Thinking globally, acting locally

BeiGene Ltd.’s hire of Pfizer Inc. veteran Xiaobing Wu is one of the loudest signals to date that regulatory and reimbursement reforms have made it attractive to develop and commercialize innovative drugs in China. Wu’s...
23:35 , May 1, 2018 |  BC Extra  |  Company News

Pfizer China GM Wu jumps to BeiGene

BeiGene Ltd. (NASDAQ:BGNE) hired Xiaobing Wu as general manager of China and president. He joins the Chinese bellwether from Pfizer Inc. (NYSE:PFE), where he was the long-serving greater China regional president and country manager for...